On Friday, Moderna Inc (NASDAQ: MRNA) opened higher 6.28% from the last session, before settling in for the closing price of $39.36. Price fluctuations for MRNA have ranged from $22.28 to $45.40 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -42.94% over the past five years. Company’s average yearly earnings per share was noted 13.72% at the time writing. With a float of $357.38 million, this company’s outstanding shares have now reached $391.00 million.
Moderna Inc (MRNA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Moderna Inc is 8.54%, while institutional ownership is 69.82%. The most recent insider transaction that took place on Dec 11 ’25, was worth 703,306. In this transaction Director of this company sold 23,853 shares at a rate of $29.48, taking the stock ownership to the 3,924 shares. Before that another transaction happened on Dec 11 ’25, when Company’s Affiliate proposed sale 23,853 for $29.49, making the entire transaction worth $703,306.
Moderna Inc (MRNA) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -2.91 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -2.76) by -0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.63% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Check out the current performance indicators for Moderna Inc (MRNA). In the past quarter, the stock posted a quick ratio of 3.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.06, a number that is poised to hit -2.61 in the next quarter and is forecasted to reach -6.75 in one year’s time.
